Industry progress report on neuro-oncology: A biotech update

Journal of Neuro-Oncology

Volumn 112, Issue 2, 2013, Pages 315-321

  Haber, Jessica S ^a   Banu, Matei A ^a   Ray, Ashley ^a   Kesavabhotla, Kartik ^a   Boockvar, John A ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Biotechnology; Cancer Therapy; Neuro oncology

Indexed keywords

ALKYLATING AGENT; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DCVAX L; DENDRITIC CELL VACCINE; DOXORUBICIN; FLUCYTOSINE; GB 13; ICT 107; IMMUNOMODULATING AGENT; LOMUSTINE; NOVOTTF 100A; PALIFOSFAMIDE; PROCARBINE; TEMOZOLOMIDE; TH 302; TRABERDERSEN; TVI BRAIN 1; UNCLASSIFIED DRUG; VAL 083; VINCRISTINE; VOCIMAGENE AMIRETROREPVEC; DRUG;

ADAPTIVE IMMUNITY; APHASIA; ASTROCYTOMA; BIOMEDICINE; BIOTECHNOLOGY; BLOOD TOXICITY; BRAIN CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; COMMERCIAL PHENOMENA; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONVULSION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DNA ALKYLATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; FEVER; GLIOBLASTOMA; GLIOMA; HEALTH CARE QUALITY; HEMIPARESIS; HEMIPLEGIA; HUMAN; HYPERTHERMIA; IMMUNE RESPONSE; INVESTMENT; MASS COMMUNICATION; MAXIMUM TOLERATED DOSE; MEDICINE; MITOSIS SPINDLE; MYELOID LEUKEMIA; NEUROLOGIC DISEASE; NEUROONCOLOGY; ORGANIZATIONAL DEVELOPMENT; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOFT TISSUE SARCOMA; SOLID TUMOR; STEM CELL; SURGICAL APPROACH; SURGICAL EQUIPMENT; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR DIAGNOSIS; ARTICLE; BRAIN TUMOR; MOLECULARLY TARGETED THERAPY; RESEARCH;

BIOTECHNOLOGY; BRAIN NEOPLASMS; DRUG INDUSTRY; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; RESEARCH REPORT;

EID: 84883744887     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-1036-8     Document Type: Conference Paper

References (26)

1. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A et al (2011) Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-oncology 13(1):132-142
2. Carpentier A, Chauvet D, Reina V, Beccaria K, Leclerq D, McNichols RJ et al (2012) MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas. Lasers Surg Med 44(5):361-368
3. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH et al (2011) A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 80(1-2):50-56
4. Hawasli AH, Ray WZ, Murphy RK, Dacey RG Jr, Leuthardt EC (2012) Magnetic resonance imaging-guided focused laser interstitial thermal therapy for subinsular metastatic adenocarcinoma: technical case report. Neurosurgery 70(2 Suppl Operative):332-337; discussion 8
5. Hawkins E (ed) (2012) A randomized, double-blind, controlled phase IIb study of the safety and efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. J Clin Oncol. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=114&abstractID=100393
6. Held-Feindt J, Lutjohann B, Ungefroren H, Mehdorn HM, Mentlein R (2003) Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells. J Neurooncol 63(2):117-127 (Pubitemid 36705681)
7. Helseth E, Dalen A, Unsgaard G, Vik R (1988) Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line. J Neurooncol 6(3):277-283 (Pubitemid 19022026)
8. Hlavaty J, Jandl G, Liszt M, Petznek H, Konig-Schuster M, Sedlak J et al (2011) Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol 102(1):59-69
9. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK (2006) Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 74:479-504
10. Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A et al (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 104(24):10152-10157 (Pubitemid 47175278)
11. Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD et al (2012) TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 69(6):1487-1498
12. Nakano I, Chiocca AE (2012) Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma. World Neurosurg 77(5-6):633-635
13. Pandya H, Gibo DM, Garg S, Kridel S, Debinski W (2012) An interleukin 13 receptor alpha 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro-oncology 14(1):6-18
14. Pless M, Weinberg U (2011) Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs 20(8):1099-1106
15. Rahmathulla G, Recinos PF, Valerio JE, Chao S, Barnett GH (2012) Laser interstitial thermal therapy for focal cerebral radiation necrosis: a case report and literature review. Stereotact Funct Neurosurg 90(3):192-200
16. Reimer P, Bremer C, Horch C, Morgenroth C, Allkemper T, Schuierer G (1998) MR-monitored LITT as a palliative concept in patients with high grade gliomas: preliminary clinical experience. J Magn Reson Imaging 8(1):240-244 (Pubitemid 28099585)
17. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D (2006) Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 79(1):61-65 (Pubitemid 44057419)
18. Shen H, Sun T, Ferrari M (2012) Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 19(6):367-373
19. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62(3):564-576; discussion 76
20. Stummer W, Nestler U, Stockhammer F, Krex D, Kern BC, Mehdorn HM et al (2011) Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 103(2):361-370
21. Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J et al (2012) Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108(1):89-97
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996 (Pubitemid 40349501)
23. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V et al (2012) NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48(14):2192-2202
24. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y et al (2012) Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 18(3):758-770
25. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26(2):225-239 (Pubitemid 47101660)
26. Wheeler CJ, Black KL (2009) DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18(4):509-519